Nobel Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2004
NCT00212368
First Marketed Drug
2022
sirolimus (rapamune)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Nobelpharma | NOBELPHARMA | Nobel Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Angiofibroma (Phase 3)

Apnea (Phase 3)

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Behcet Syndrome (Phase 2)

Child Development Disorders, Pervasive (Phase 3)

Cytomegalovirus Infections (Phase 2)

Disease (Phase 3)

Dysmenorrhea (Phase 3)

Endometriosis (Phase 3)

Epilepsy (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 3)

Hepatolenticular Degeneration (Phase 3)

Herpes Zoster (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Neuralgia (Phase 2)

Neurodevelopmental Disorders (Phase 3)

Neurofibroma (Phase 3)

Neurofibromatoses (Phase 3)

Neurofibromatosis 1 (Phase 3)

Parasomnias (Phase 3)

Premature Birth (Phase 3)

Sclerosis (Phase 3)

Sleep Wake Disorders (Phase 3)

Tuberous Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 38
  • # of Trial APIs: 24